Selayang Hospital, Selangor Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2011
NCT01448434
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Selayang Hospital

Active Ingredients

Drugs in Phase 3 Trials (1)

sofosbuvir (sovaldi) (1 trial)

Drugs in Phase 2 Trials (2)

allogeneic adipose derived mesenchymal stem cell (1 trial)

hepar-p (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fatty Liver (Phase 2)

Hepatitis C (Phase 3)

Liver Diseases (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3